Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
IntelGenx Corp. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'IntelGenx Corp. - Product Pipeline Review - 2014', provides an overview of the IntelGenx Corp.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of IntelGenx Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of IntelGenx Corp. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of IntelGenx Corp.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the IntelGenx Corp.'s pipeline products Reasons to buy - Evaluate IntelGenx Corp.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of IntelGenx Corp. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the IntelGenx Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of IntelGenx Corp. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of IntelGenx Corp. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of IntelGenx Corp. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 IntelGenx Corp. Snapshot 5 IntelGenx Corp. Overview 5 Key Information 5 Key Facts 5 IntelGenx Corp. - Research and Development Overview 6 Key Therapeutic Areas 6 IntelGenx Corp. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 IntelGenx Corp. - Pipeline Products Glance 13 IntelGenx Corp. - Late Stage Pipeline Products 13 Filing rejected/Withdrawn Products/Combination Treatment Modalities 13 IntelGenx Corp. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 IntelGenx Corp. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 IntelGenx Corp. - Unknown Stage Pipeline Products 18 Unknown Products/Combination Treatment Modalities 18 IntelGenx Corp. - Drug Profiles 19 rizatriptan benzoate 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 eszopiclone 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 INT-0028 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 tadalafil 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 INT-0024 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 INT-0031 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 INT-0035 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 INT-0036 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 INT-0029 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 metoprolol succinate 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 IntelGenx Corp. - Pipeline Analysis 30 IntelGenx Corp. - Pipeline Products by Target 30 IntelGenx Corp. - Pipeline Products by Route of Administration 31 IntelGenx Corp. - Pipeline Products by Molecule Type 32 IntelGenx Corp. - Pipeline Products by Mechanism of Action 33 IntelGenx Corp. - Recent Pipeline Updates 34 IntelGenx Corp. - Dormant Projects 36 IntelGenx Corp. - Locations And Subsidiaries 37 Head Office 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables IntelGenx Corp., Key Information 5 IntelGenx Corp., Key Facts 5 IntelGenx Corp. - Pipeline by Indication, 2014 8 IntelGenx Corp. - Pipeline by Stage of Development, 2014 9 IntelGenx Corp. - Monotherapy Products in Pipeline, 2014 10 IntelGenx Corp. - Partnered Products in Pipeline, 2014 11 IntelGenx Corp. - Partnered Products/ Combination Treatment Modalities, 2014 12 IntelGenx Corp. - Filing rejected/Withdrawn, 2014 13 IntelGenx Corp. - Phase II, 2014 14 IntelGenx Corp. - Phase I, 2014 15 IntelGenx Corp. - Preclinical, 2014 16 IntelGenx Corp. - Discovery, 2014 17 IntelGenx Corp. - Unknown, 2014 18 IntelGenx Corp. - Pipeline by Target, 2014 30 IntelGenx Corp. - Pipeline by Route of Administration, 2014 31 IntelGenx Corp. - Pipeline by Molecule Type, 2014 32 IntelGenx Corp. - Pipeline Products by Mechanism of Action, 2014 33 IntelGenx Corp. - Recent Pipeline Updates, 2014 34 IntelGenx Corp. - Dormant Developmental Projects,2014 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.